ACOT11

Across TCGA pan-cancer cohorts, ACOT11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACOT11 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACOT11 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACOT11 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and LUAD are the cancer types where ACOT11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.466	0.297	.011	50	view →
COAD	DFS	Median	II,III,IV	1.000	0.912	.014	36	view →
LUAD	OS	Quartile	II,III,IV	0.304	0.871	.010	15	view →
HNSC	OS	Quartile	IV	0.964	0.698	.025	3	view →
UCEC	OS	Median	All	0.991	0.910	.033	2	view →
LSCC	OS	Quartile	III,IV	0.898	0.381	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACOT11–PDAC (OS)

Open the PDAC breakdown →